Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK SHAHRAM SHAHIN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1568440451
CMS profile
26005
Location
HERSHEY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$170,886.48

188 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK SHAHRAM SHAHIN

NPI 1568440451 · CMS profile ID 26005

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

HERSHEY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568440451?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK SHAHRAM SHAHIN, NPI 1568440451, CMS profile ID 26005. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568440451?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARK SHAHRAM SHAHIN, NPI 1568440451, CMS profile ID 26005. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568440451?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARK SHAHRAM SHAHIN, NPI 1568440451, CMS profile ID 26005, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1568440451?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

188 matching records · $170,886.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 188 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 188.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $629.9510/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116420601 CMS
AstraZeneca Pharmaceuticals LP $3,607.5010/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110532095 CMS
Corcept Therapeutics $34.8310/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117769314 CMS
Eisai Inc. $124.4110/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110763823 CMS
Karyopharm Therapeutics Inc. $102.9810/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145533333 CMS
GlaxoSmithKline, LLC. $4,800.0010/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116420355 CMS
Merck Sharp & Dohme LLC $3,050.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141583077 CMS
Merck Sharp & Dohme LLC $150.0010/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141583175 CMS
Merck Sharp & Dohme LLC $4,270.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141830318 CMS
Novartis Pharmaceuticals Corporation $23.8410/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087317493 CMS
Genmab U.S., Inc. $24.4809/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126829462 CMS
Merck Sharp & Dohme LLC $50.3509/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141582809 CMS
Merck Sharp & Dohme LLC $919.5009/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141583207 CMS
GlaxoSmithKline, LLC. $800.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116488960 CMS
GlaxoSmithKline, LLC. $4,800.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115752698 CMS
GlaxoSmithKline, LLC. $972.7009/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115853845 CMS
GlaxoSmithKline, LLC. $96.3809/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116447036 CMS
GlaxoSmithKline, LLC. $4,800.0009/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116278734 CMS
ABBVIE INC. $43.3009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106069172 CMS
Daiichi Sankyo Inc. $25.9209/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089481213 CMS
Apellis Pharmaceuticals, Inc. $24.6609/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154025631 CMS
GlaxoSmithKline, LLC. $10.0009/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115848272 CMS
GlaxoSmithKline, LLC. $77.5809/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116403705 CMS
GlaxoSmithKline, LLC. $18.2308/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116428982 CMS
GlaxoSmithKline, LLC. $48.8508/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116014290 CMS
GlaxoSmithKline, LLC. $1,078.0008/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116467110 CMS
GlaxoSmithKline, LLC. $4,800.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116625928 CMS
ABBVIE INC. $3,854.0008/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106069170 CMS
BeiGene USA, Inc. $19.2808/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120853962 CMS
Genmab U.S., Inc. $109.6208/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126829468 CMS
Karyopharm Therapeutics Inc. $97.8608/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145533329 CMS
GlaxoSmithKline, LLC. $4,800.0008/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116361195 CMS
GlaxoSmithKline, LLC. $4,800.0008/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116654499 CMS
Merck Sharp & Dohme LLC $33.6408/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141830330 CMS
ABBVIE INC. $125.0008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106069166 CMS
ABBVIE INC. $921.9108/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106069168 CMS
GlaxoSmithKline, LLC. $4.8208/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116459043 CMS
GlaxoSmithKline, LLC. $400.0008/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115817978 CMS
Ipsen Biopharmaceuticals, Inc $21.2908/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091986497 CMS
GlaxoSmithKline, LLC. $123.0007/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116313193 CMS
GlaxoSmithKline, LLC. $1,961.7307/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116467422 CMS
GlaxoSmithKline, LLC. $169.8807/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116480431 CMS
Myriad Genetic Laboratories, Inc. $91.5007/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152539973 CMS
ABBVIE INC. $32.1907/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106069164 CMS
Eisai Inc. $90.5007/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110763815 CMS
GlaxoSmithKline, LLC. $4,800.0007/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116605622 CMS
Merck Sharp & Dohme LLC $915.0007/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141833001 CMS
GlaxoSmithKline, LLC. $124.4507/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116269585 CMS
GlaxoSmithKline, LLC. $1,237.6807/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116398512 CMS
Novartis Pharmaceuticals Corporation $17.6207/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087317483 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $147,253.65 170
PY2020 $82,689.24 56
PY2021 $83,480.03 62
PY2022 $145,890.53 131
PY2023 $107,388.82 129
PY2024 $170,886.48 188
PY2025 $176,544.44 180

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $286,459.43 29
PY2024 Principal investigator $112,841.43 13
PY2023 Principal investigator $76,043.13 13
PY2022 Principal investigator $240,563.11 22
PY2021 Principal investigator $736,855.49 38
PY2020 Principal investigator $516,585.62 46
PY2019 Principal investigator $1,003,650.13 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $7,914.00 12/22/2025 Covered Recipient Teaching Hospital
ABINGTON MEMORIAL HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192100363
Principal investigator 1 GlaxoSmithKline, LLC. $6,762.50 12/22/2025 Covered Recipient Teaching Hospital
ABINGTON MEMORIAL HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192145524
Principal investigator 1 Genmab U.S., Inc. $2,093.28 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933810
Principal investigator 1 Genmab U.S., Inc. $2,046.24 12/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933822
Principal investigator 1 Genmab U.S., Inc. $6,138.72 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933846
Principal investigator 1 GlaxoSmithKline, LLC. $8,460.41 12/04/2025 Covered Recipient Teaching Hospital
THOMAS JEFFERSON UNIV. HOSPITAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB No dispute reported 06/30/2026 1192104075
Principal investigator 1 Genmab U.S., Inc. $2,093.28 11/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933920
Principal investigator 1 Genmab U.S., Inc. $4,173.62 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933903
Principal investigator 1 Genmab U.S., Inc. $3,138.74 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933855
Principal investigator 1 Genmab U.S., Inc. $6,185.76 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933923
Principal investigator 1 Genmab U.S., Inc. $2,634.24 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933837
Principal investigator 1 Genmab U.S., Inc. $22,225.22 10/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933926
Principal investigator 1 GlaxoSmithKline, LLC. $1,970.00 10/15/2025 Covered Recipient Teaching Hospital
THOMAS JEFFERSON UNIV. HOSPITAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192104082
Principal investigator 1 Genmab U.S., Inc. $22,792.05 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933917
Principal investigator 1 pharmaand GmbH $2,137.50 09/25/2025 Non-covered Recipient Entity
Thomas Jefferson University (PA121)
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992341
Principal investigator 1 Genmab U.S., Inc. $34,893.08 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235934342
Principal investigator 1 GlaxoSmithKline, LLC. $2,012.04 09/04/2025 Non-covered Recipient Entity
ABINGTON MEMORIAL HOSP
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192179749
Principal investigator 1 Genmab U.S., Inc. $92,472.36 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235934283
Principal investigator 1 GlaxoSmithKline, LLC. $1,970.00 07/17/2025 Covered Recipient Teaching Hospital
THOMAS JEFFERSON UNIV. HOSPITAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192101541
Principal investigator 1 GlaxoSmithKline, LLC. $7,191.80 07/01/2025 Non-covered Recipient Entity
ABINGTON MEMORIAL HOSP
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192179758
Principal investigator 1 GlaxoSmithKline, LLC. $15,950.00 06/25/2025 Non-covered Recipient Entity
ABINGTON MEMORIAL HOSP
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192179766
Principal investigator 1 GlaxoSmithKline, LLC. $2,012.04 06/20/2025 Non-covered Recipient Entity
ABINGTON MEMORIAL HOSP
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192179754
Principal investigator 1 pharmaand GmbH $855.00 06/18/2025 Non-covered Recipient Entity
Thomas Jefferson University (PA121)
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992339
Principal investigator 1 pharmaand GmbH $3,375.00 05/19/2025 Non-covered Recipient Entity
Thomas Jefferson University (PA121)
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992337
Principal investigator 1 GlaxoSmithKline, LLC. $2,012.04 05/02/2025 Non-covered Recipient Entity
ABINGTON MEMORIAL HOSP
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192179762
Principal investigator 1 GlaxoSmithKline, LLC. $8,460.41 04/21/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY HOSPITAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB No dispute reported 06/30/2026 1192123009
Principal investigator 1 pharmaand GmbH $2,565.00 04/14/2025 Non-covered Recipient Entity
Thomas Jefferson University (PA121)
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992335
Principal investigator 1 GlaxoSmithKline, LLC. $6,895.00 03/03/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY HOSPITAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192123002
Principal investigator 1 GlaxoSmithKline, LLC. $5,030.10 02/21/2025 Non-covered Recipient Entity
ABINGTON MEMORIAL HOSP
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192122996